Shares of iCAD, Inc. (NASDAQ:ICAD - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.55 and traded as high as $3.90. iCAD shares last traded at $3.77, with a volume of 358,509 shares trading hands.
Analyst Ratings Changes
Several research analysts recently issued reports on ICAD shares. Wall Street Zen started coverage on shares of iCAD in a report on Tuesday, May 20th. They set a "sell" rating for the company. Laidlaw reaffirmed a "hold" rating on shares of iCAD in a research report on Thursday, April 17th. Craig Hallum lowered iCAD from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Finally, BTIG Research cut iCAD from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th.
Get Our Latest Analysis on ICAD
iCAD Stock Up 1.0%
The business's 50-day simple moving average is $3.13 and its two-hundred day simple moving average is $2.57. The firm has a market cap of $107.14 million, a price-to-earnings ratio of -30.00 and a beta of 1.38.
iCAD (NASDAQ:ICAD - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The technology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.04. The company had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.54 million. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of ICAD. Parkman Healthcare Partners LLC acquired a new stake in iCAD in the 1st quarter worth about $1,610,000. First Eagle Investment Management LLC lifted its position in shares of iCAD by 6.1% in the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company's stock valued at $1,311,000 after acquiring an additional 41,000 shares in the last quarter. Informed Momentum Co LLC acquired a new stake in shares of iCAD in the first quarter worth approximately $593,000. Geode Capital Management LLC increased its position in shares of iCAD by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock worth $506,000 after purchasing an additional 17,059 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in iCAD in the 1st quarter valued at $505,000. Institutional investors and hedge funds own 24.61% of the company's stock.
iCAD Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Read More
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
